HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells by Dai, Bingbing et al.
Supporting Information
Dai et al. 10.1073/pnas.0911742106
SI Text
Vaccination Procedure. The DNA-based immunization protocol
involved the injection of 50-g Gag-encoded plasmid DNA
intramuscularly three times successively at 3-week intervals (1).
For immunization with viral vectors, mice were injected with
replication-defective rAd5-Gag [1  1010 VP (Viral Particles)]
via an f.p. route or LV-Gag [5  106 TU (Transduction Units)]
using the indicated routes. For the DNA/rAd5-Gag and DNA/
LV-Gag immunization regimens, animals were given three con-
secutive intramuscular injections of plasmid DNA (50 g each)
as priming, followed by a booster injection of rAd5-Gag (1 1010
VP) or LV-Gag (5  106 TU) f.p. 3 weeks after the last DNA
injection. For the LV-Gag/LV-Gag homologous immunization,
mice were primed with the LV-Gag (5  106 TU) f.p. and
boosted with the same vector and dose i.d. (at the base of tail)
4 weeks thereafter. The mice vaccinated by a single injection of
LV-Gag were analyzed for their immune responses 2 weeks
postinjection. The rAd5-Gag immunized mice were analyzed 3
weeks postinjection. The animals with prime/boost vaccinations
were analyzed 2 weeks after the final injection.
Vector Production. The LV-Gag vector was produced by transient
transfection of 293T cells using a standard calcium phosphate
precipitation protocol. 293T cells cultured in a 15-cm tissue
culture dish (BD Biosciences) were transfected with the follow-
ing plasmids: the lentiviral backbone plasmid FUWGag (37.5
g), the SVGmu-encoding envelope plasmid (18.75 g), and the
packaging plasmids (pMDLg/pRRE and pRSV-Rev, 18.75 g
for each). The viral supernatant was harvested twice at both 48
and 72 h posttransfection, combined and filtered through a
0.45-mm filter (Corning). The concentrated viral pellets were
obtained after ultracentrifugation of the viral supernatants at
50,000  g for 90 min, and were then resuspended in an
appropriate volume of cold PBS for in vivo study. The Gag-
encoded and E1/E3-deleted adenovirus serotype 5 vector (rAd5-
Gag) was constructed and produced according to the procedure
provided by the manufacturer (ViraPower Adenoviral Expres-
sion System, Invitrogen). The Gag-encoding plasmid for the
DNA vaccine was generously provided by Dr. Gary Nabel of the
National Institutes of Health Vaccine Research Center (Be-
thesda, Maryland) and the endotoxin-free plasmid DNA was
produced using a Qiagen kit (Qiagen) for the immunization of
mice.
Gag Peptide and Peptide Pool. The immunodominant H2-Kd-
restricted CD8 T-cell epitope (AMQMLKETI, amino acids
197–205) is derived from the p24 portion of theGag protein. This
peptide was synthesized (GenScript) and dissolved in dimethyl
sulfoxide (DMSO) at 8 mg/mL. The Gag peptide pool includes
123 15-mer peptides overlapping by 10–11 amino acids and
spanning the entire HIV-1 subtype B Gag sequence. Individual
peptides in this library were dissolved in DMSO at 10 mg/mL,
and stored at 80 °C.
Tetramer Staining and Phenotypic Analysis. The phycoerythrin
(PE)-conjugated major histocompatibility complex (MHC) class
I tetramer H2-Kd-AMQMLKETI was obtained from Beckman
Coulter. At indicated time points after immunization, tetramer-
specific and phenotypic properties were evaluated on spleen cells
harvested from vaccinated and control mice. Surface staining
was performed by blocking the Fc receptors of cells with an
anti-mouse CD16/CD32 antibody (clone 2.4G2, BD Bio-
sciences), followed by incubating the cells with tetramer along
with other f luorochrome-conjugated antibodies, including
FITC-, PE-Cy5- or APC- conjugated antibodies specific for
mouse CD8, CD44, CD62L (BD Biosciences). The flow cytom-
etry analysis was conducted using either the FACSort or the
FACSCalibur instrument (BD Biosciences).
Intracellular Cytokine Staining (ICCS) and Multiparameter ICCS.
Splenocytes from immunized or control mice (1  106/sample)
were pooled and incubated with the HIV Gag peptide (AMQM-
LKETI) (4 g/mL) in the presence of costimulatory anti-CD28
antibody (2 g/mL, BD Biosciences) for 1 h at 37 °C in a 96-well
round-bottom plate in RPMI medium supplemented with 10%
FBS (Sigma), 10 U/mL penicillin, 100 g/mL streptomycin, and
2 mM glutamine. Brefeldin A (BFA, Sigma) was added (10
g/mL) to wells to inhibit cytokine exporting for another 4 h.
Surface staining was performed by incubating restimulated cells
with anti-mouse CD16/CD32 antibody, followed by anti-mouse
CD8 and anti-mouse CD4 antibodies. Cells were then perme-
abilized in 100 L Cytofix/Cytoperm solution (BD Biosciences)
at 4 °C for 20 min, washed with Perm/Wash buffer (BD Bio-
sciences), and followed by intracellular staining with PE-
conjugated anti-mouse IFN- at 4 °C for 30 min. The flow
cytometry analysis was carried out using the FACSort instru-
ment from BD Biosciences. A similar procedure was used for the
multiparameter ICCS, except that the splenocytes were stimu-
lated by the pooled HIV-1 Gag peptides (2.5 g/mL for each
peptide) and the resulting cells were incubated with the viability
dye (ViViD, Invitrogen) and stained with the following surface
monoclonal antibodies: anti-CD4-PerCP, anti-CD8-APC-Cy7,
anti-CD3-Alexa488, and intracellular monoclonal antibodies:
anti-IL-2-PE, anti-IFN--APC, and anti-TNF--PE-Cy7. ICCS
data were acquired on a BD LSR II flow cytometer. All of the
staining antibodies were purchased from (BD Biosciences).
ELISA. Antibody responses were assessed by ELISA using the
method described before (2). PBST (PBS containing 0.2%
Tween 20) was prepared as wash buffer, and three to five times
of extensive washes were conducted each time before adding new
reagents to plates. ELISA plates were coated with Galanthus
nivalis lectin 100 L/well (10 g/mL, Sigma) overnight at 4 °C,
followed by blocked with PBSS (PBS containing 10% FBS) at
200 L/well, 2 h, and room temperature. To evaluate Gag-
specific antibody response, 293T cells were transfected with
FUWGag (100 L) 48 h before the time of assaying ELISA.
Supernatant of transfected cells was collected, and was added to
the plates (100 L/well) for 1 h of incubation at room temper-
ature. Sera from immunized mice of different groups were
diluted 2-fold serially (in PBSS) and 100 L were added to each
well for 1 h. The plates were then treated with 100 L horse-
radish peroxidase (HRP)-labeled anti-mouse IgG or IgM anti-
body (1:10,000 dilution) for an additional 1 h. Finally, color
development was accomplished by using 100 L per well of
tetramethylbenzidine (TMB) substrate solution (KPL) for 45
min at 37 °C, and stopped by 100 L of 2 M H2SO4. Titer was
reported as the reciprocal of endpoint dilutions, at which the
absorbance readings at the wavelength of 450 nm (OD450) were
at least 0.2 OD greater than that of the control groups. The
optical density was measured using a plate reader (Molecular
Devices).
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IFN- ELISPOT Assay. ELISPOT assays were performed for IFN-
using a kit from Millipore according to the manufacturer’s
instruction. Briefly, anti-mouse IFN- antibody (10 g/mL in
PBS) was used as the capture antibody and plated 100 L/well
on 96-wellMultiScreen-IP plates overnight at 4 °C. The plate was
decanted and blocked with RPMI medium containing 10% FBS
at 37 °C for 2 h. Splenocytes from mice were plated at 1  105
cells/well in 150 L complete medium in company with stimulus,
which are HIV-1 Gag single peptide (2 g/mL) or pools of
peptides (at a final concentration of 3 g/mL for each peptide)
for this assay. After 18 h incubation at 37 °C, cells were lysed by
water and plates were detected by 0.5 g/mL biotinylated
anti-IFN- antibody (BD Biosciences) for 2 h at room temper-
ature. Plates were further washed and incubated with the
1,000-fold-diluted streptavidin-alkaline phosphate conjugate for
45 min at room temperature. After a final extensive wash, spots
were identified by addition of BCIP/NBTplus substrate, and the
number of IFN- producing cells was quantified by an ELISPOT
reader.
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Fig. S1. Confirmationof the response of T cells fromLV-Gag/LV-Gagmice to individual peptides derived from thepeptide pool study. The amino acid sequences
of these peptides are: 1, eeeqnkskkkaqqaa; 2, nkskkkaqqaaadtg; 3, kkaqqaaadtghsnq; 4, sqnypivqniqgqmv, 5, amqmlketineeaae; 6, lketineeaaewdrv; 7,
drvhpvhagpiapgq; 8, pvhagpiapgqmrep; 9, stlqeqigwmtnnpp; 10, pvgeiykrwiilgln; and 11, iykrwiilglnkivr.
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Fig. S2. Intracellular cytokine staining (ICCS) analysis of splenocytes harvested from LV-Gag/LV-Gag vaccinatedmice and stimulated by two representative and
highly reactive peptide pools (P6 and P10). Gag-specific CD4 and CD8 T-cell responses can be assessed by ICCS staining of IFN- alongwith the surface costaining
of CD4 and CD8.
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